Alector Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Alector kazanç ve gelirin sırasıyla yıllık 38.8% ve 40.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 43.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -150.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

38.8%

Kazanç büyüme oranı

43.29%

EPS büyüme oranı

Biotechs kazanç büyümesi	23.9%
Gelir büyüme oranı	40.2%
Gelecekteki özkaynak getirisi	-150.93%
Analist kapsamı	Good
Son güncelleme	13 May 2025

Gelecekteki son büyüme güncellemeleri

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

May 11

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Mar 01

Recent updates

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

May 11

Alector, Inc. (NASDAQ:ALEC) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

May 05

ABC Platform And Latozinemab Trial Will Yield Mixed Prospects

Apr 03 Alector's ABC platform and late-stage trials, like those for latozinemab, could significantly boost revenue if successful, addressing unmet medical needs.

Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26%

Mar 21

Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point

Mar 13

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Mar 01

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 53%

Dec 23

Need To Know: Analysts Just Made A Substantial Cut To Their Alector, Inc. (NASDAQ:ALEC) Estimates

Nov 28

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Jan 19

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Sep 25

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Jun 27

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Mar 02

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Jan 16

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Oct 04

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:ALEC - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	96	-125	-131	-93	5
12/31/2026	59	-161	-122	-108	7
12/31/2025	12	-178	-101	-91	7
3/31/2025	88	-123	-230	-229	N/A
12/31/2024	101	-119	-231	-230	N/A
9/30/2024	62	-158	-222	-221	N/A
6/30/2024	55	-161	-218	-217	N/A
3/31/2024	96	-121	-199	-197	N/A
12/31/2023	97	-130	-187	-184	N/A
9/30/2023	96	-141	-190	-187	N/A
6/30/2023	102	-143	-194	-190	N/A
3/31/2023	126	-135	-208	-204	N/A
12/31/2022	134	-133	-24	-20	N/A
9/30/2022	133	-136	-25	-21	N/A
6/30/2022	301	36	471	473	N/A
3/31/2022	227	-29	483	486	N/A
12/31/2021	207	-36	295	299	N/A
9/30/2021	198	-33	297	300	N/A
6/30/2021	21	-212	-189	-186	N/A
3/31/2021	18	-202	-190	-187	N/A
12/31/2020	21	-190	-172	-167	N/A
9/30/2020	22	-169	-154	-148	N/A
6/30/2020	19	-148	-144	-136	N/A
3/31/2020	23	-127	-125	-108	N/A
12/31/2019	21	-105	-115	-99	N/A
9/30/2019	24	-92	-102	-88	N/A
6/30/2019	28	-76	-94	-82	N/A
3/31/2019	28	-62	-84	-81	N/A
12/31/2018	28	-52	N/A	127	N/A
9/30/2018	22	-45	N/A	143	N/A
6/30/2018	15	-39	N/A	159	N/A
3/31/2018	8	-35	N/A	171	N/A
12/31/2017	4	-32	N/A	-18	N/A
12/31/2016	0	-15	N/A	-13	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ALEC önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.8% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: ALEC önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: ALEC önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: ALEC şirketinin gelirinin (yıllık 40.2% ) US pazarından (yıllık 8.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ALEC şirketinin gelirinin (yıllık 40.2% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ALEC 3 yıl içinde kârsız olması bekleniyor.

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/19 05:13
Gün Sonu Hisse Fiyatı	2025/05/16 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Alector, Inc. 15 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Alec Stranahan	BofA Global Research
Thomas Shrader	BTIG
Pete Stavropoulos	Cantor Fitzgerald & Co.

Alector Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates decrease by 14%, EPS upgraded

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

Price target decreased by 7.9% to US$4.22

Consensus revenue estimates fall by 67%

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Alector, Inc. Provides Revenue Guidance for the Year Ending 2025

Recent updates

Consensus revenue estimates decrease by 14%, EPS upgraded

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc. (NASDAQ:ALEC) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Alector, Inc., Annual General Meeting, Jun 11, 2025

New minor risk - Share price stability

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease

New minor risk - Market cap size

ABC Platform And Latozinemab Trial Will Yield Mixed Prospects

Alector Provides Executive Leadership Update

Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26%

Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point

Co-Founder recently sold US$59k worth of stock

Price target decreased by 7.9% to US$4.22

Consensus revenue estimates fall by 67%

Co-Founder notifies of intention to sell stock

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. Provides Revenue Guidance for the Year Ending 2025

Insufficient new directors

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 53%

Price target decreased by 22% to US$6.33

Co-Founder recently sold US$131k worth of stock

Co-Founder notifies of intention to sell stock

Need To Know: Analysts Just Made A Substantial Cut To Their Alector, Inc. (NASDAQ:ALEC) Estimates

Alector: Bleak Prospects After Alzheimer's Failure

Price target decreased by 37% to US$10.28

Alector, Inc. Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’S Disease and Provides Business Update

Alector, Inc. announced that it expects to receive $50 million in funding from Hercules Capital, Inc., and other investors

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

Alector, Inc. Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Co-Founder recently sold US$129k worth of stock

Co-Founder recently sold US$129k worth of stock

Board Member recently sold US$228k worth of stock

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Co-Founder recently sold US$121k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024

First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.55 loss in 1Q 2023)

Alector, Inc., Annual General Meeting, Jun 12, 2024

Co-Founder recently sold US$130k worth of stock

Consensus revenue estimates decrease by 37%, EPS upgraded

Co-Founder notifies of intention to sell stock

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’S Disease

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $71.413049 million.

New minor risk - Shareholder dilution

Alector, Inc. has filed a Follow-on Equity Offering.

Alector: Good Data, Huge Cash, No Near Term Catalyst

Insufficient new directors

New major risk - Revenue and earnings growth

Co-Founder recently sold US$133k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023

Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)